Figure 2.

MRD response and survival outcomes. (A) Flow cytometric MRD levels in bone marrow after course 1 according to treatment arm. Median levels, presented as a percentage, were significantly lower in the GO2 arm (median, 25%-75% quartiles with 1-99 percentiles are shown). Comparisons were performed using the Mann-Whitney U test for continuous variables. Patients with MRD <0.1% were 72% (218 of 302) in the GO2 arm and 62% (191 of 307) in the GO1 arm. Patients with undetectable MRD were 57% (173 of 302) in the GO2 arm and 49.5% (152 of 307) in the GO1 arm. Results represent all patients with MRD data (including those not in CR/CRi after course 1). (B) OS. (C) OS of patients without adverse cytogenetics or mutated TP53.